drugset / Trial / NCT00652730
Bioavailability Study of (Buspar) Buspirone HCl Tablets Under Fasting and Fed Conditions
Phase 1
Completed
21 enrolled
Par Pharmaceutical, Inc.
Phoenix International Life Sciences, Inc. · collab
RandomizedCrossoverOpen-labelOther
Summary
To compare the single-dose bioavailability of Par and Bristol-Myers Squibb Buspirone HCl Tablets
Timeline
- Start
- 1998-07
- Primary completion
- 1998-09
- Completion
- 1998-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Buspirone | Small molecule | 30 mg | — |
Indications
No indication recorded.